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Abstract 
 
Background/objectives: The most recent ACC/AHA guidelines recommend high-intensity statin therapy in 
ischemic stroke patients of presumably atherosclerotic origin. On the contrary, there is no specific 
recommendation for the use of statin in patients with non-atherosclerotic stroke, e.g. strokes related to 
atrial fibrillation (AF). We investigated whether statin treatment in patients with AF-related stroke is 
associated with improved survival and reduced risk for stroke recurrence and future cardiovascular 
events. 
Methods: All consecutive patients registered in the Athens Stroke Registry with AF-related stroke and no 
history of coronary artery disease nor clinically manifest peripheral artery disease were included in the 
analysis and categorized in two groups depending on whether statin was prescribed at discharge. The 
primary outcome was overall mortality; the secondary outcomes were stroke recurrence and a composite 
cardiovascular endpoint comprising of recurrent stroke, myocardial infarction, aortic aneurysm rupture or 
sudden cardiac death during the 5-year follow-up.   
Results: Among 1602 stroke patients, 404 (25.2%) with AF-related stroke were included in the analysis, of 
whom 102 (25.2%) were discharged on statin. On multivariate Cox-proportional-hazards model, statin 
treatment was independently associated with a lower mortality (hazard-ratio (HR): 0.49, 95%CI:0.26-0.92) 
and lower risk for the composite cardiovascular endpoint during the median 22 months follow-up (HR: 
0.44, 95%CI:0.22-0.88), but not with stroke recurrence (HR: 0.47, 95%CI:0.22-1.01, p:0.053). 
Conclusions: In this long-term registry of patients with AF-related stroke, statin treatment was associated 
with improved survival and reduced risk for future cardiovascular events.   
 
Keywords: stroke recurrence; atrial fibrillation; statin; mortality 
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Introduction 
 
The recent ACC/AHA guidelines recommend high-intensity statin therapy in patients with ischemic stroke 
of presumably atherosclerotic origin[1]. On the contrary, there is no specific recommendation for statin 
treatment in patients with non-atherosclerotic stroke, e.g. strokes related to atrial fibrillation (AF), 
because evidence is very scarce. AF was an exclusion criterion in the Stroke Prevention by Aggressive 
Reduction in Cholesterol Levels (SPARCL) trial[2]. On the other hand, patients with AF-related stroke are 
considered a high-risk group not only for stroke recurrence but also for future cardiovascular events and 
death[3-5].  Clinicians therefore remain uncertain whether to initiate statin treatment in such patients. 
Recently, a retrospective study in a Korean stroke registry showed that statin treatment could be 
associated with reduced mortality in patients with cardioembolic stroke[6]. 
 
The aim of the present study was to investigate in a non-randomized patient population whether statin 
treatment in patients with AF-related stroke is associated with improved survival and reduced risk for 
stroke recurrence and future cardiovascular events.  
 
 
Methods 
Study population and definitions 
The study population was derived from the Athens Stroke Registry which includes all consecutive patients 
with an acute first-ever ischemic stroke admitted in Alexandra University Hospital, Athens, Greece 
between January 2000 and December 2011[7]. Patients with transient ischaemic attack (TIA) or recurrent 
stroke are not included in the registry. Patients with AF-related stroke and no history of coronary artery 
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disease (CAD) were included in the analysis irrespective of their baseline LDL levels. Baseline LDL levels 
were not an inclusion criterion because patients with cardioembolic stroke are a high-risk group for future 
cardiovascular events and increased cardiovascular and overall mortality[4].  
Detailed data were prospectively recorded including demographics, medical history and associated 
cardiovascular risk factors, current medication, time of stroke onset and hospital admission, duration of 
hospitalization, stroke characteristics, clinical findings and vital signs on admission, laboratory 
investigations and treatment. Stroke severity was assessed by means of the National Institute Health 
Stroke Scale score (NIHSS) at admission. Stroke subtype was classified according to the Trial of Org 10172 
in Acute Stroke Treatment (TOAST) criteria[8]. Patients were prospectively followed-up at 1, 3, and 6 
months after discharge and yearly thereafter. Follow-up was routinely performed in the outpatient clinic. 
In case of patients with severe handicap, clinical follow-up was assessed at patient’s residence or by 
telephone interview. The scientific use of the data collected in the Athens Stroke Registry was approved 
by the local Ethics Committee. 
 
Hypertension was defined as systolic blood pressure >140mmHg and/or diastolic blood pressure 
>90mmHg diagnosed at least twice before stroke or if patient was already on antihypertensives[9]. 
Diabetes mellitus was defined if patient was already on antidiabetic drugs and/or insulin, or if fasting 
blood glucose level was >6.0mmol/l before stroke[10]. Dyslipidemia was defined as cholesterol 
concentration >6.5 mmol/l the day after admission, or if patient had a previous diagnosis of 
dyslipidemia[11]. Coronary heart disease was assessed by questionnaire and relevant medical 
confirmation. Heart failure was defined according to the criteria recommended by the working group on 
heart failure of the European Society of Cardiology[12]. TIA was defined as complete disappearance of 
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signs and symptoms within 24 hours, regardless of infarction being shown on neuroimaging[13]. Stroke 
was defined according to the World Health Organization criteria[14]. 
A 12-lead electrocardiogram (ECG) was recorded at admission in all patients. In patients on sinus rhythm, 
paroxysms of AF were sought by means of repeated ECGs during hospital stay, and/or continuous ECG 
monitoring for several days for patients treated in the stroke unit, and/or 24-hours Holter ECG monitoring 
(when AF was strongly suspected from the clinical presentation and brain imaging findings). In patients 
with at least two episodes of AF lasting ≥30seconds during such monitoring, the stroke was considered as 
potentially AF-related, and they were selected for the analysis. These ppatients were then categorized in 
two groups according to whether a statin was prescribed at discharge. 
 
Outcomes and follow-up 
The primary outcome of this study was overall mortality during the follow-up performed up to 5 years. 
The secondary outcomes were stroke recurrence and a composite cardiovascular endpoint comprising of 
recurrent stroke, myocardial infarction, aortic aneurysm rupture or sudden cardiac death during the 
follow-up up to 5 years. Death and its causes were assessed from death certificates, patients’ hospital 
records and information from general practitioners or family physicians.  
  
Statistical Analysis 
 
Continuous data are summarized as mean value and standard deviation (SD), and categorical data as 
absolute numbers and proportion. Dichotomous or categorical variables were compared with the x2 test 
and continuous variables were compared with the unpaired t-test or Mann-Whitney U test. For patients 
lost during follow-up, survival data were censored at the last time known to be alive. Patients who 
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experienced >1 composite vascular event during the follow-up period were censored at the time of the 
first event.  
 
The Kaplan–Meier product limit method was used to estimate the probability of each outcome. 
Differences in Kaplan–Meier curves among the on-statin and off-statin groups were evaluated with the 
log-rank test. To evaluate if statin treatment is an independent predictor of outcome, univariate Cox 
proportional hazards analyses were initially performed for each study outcome. The covariates studied in 
these univariate analyses were age, sex, onset to admission time, stroke severity (assessed by the NIHSS 
score), TOAST mechanism, cardiovascular risk factors and comorbidities, prestroke medication, main 
laboratory findings at admission and basic findings on brain imaging at admission. Factors that were 
significant in the univariate analyses were included in the multivariate Cox model. For the univariate 
analysis, the level of significance was set at 10% to reduce the risk of a type II error. In the final 
multivariate analyses, the level of significance was set at 5%. Associations are presented as hazard ratios 
(HR) with their corresponding 95% confidence intervals (95% CI).  Statistical analyses were performed 
with the Statistical Package for Social Science (SPSS Inc., version 10.0 for Windows).  
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Results 
 
Among 1602 patients admitted with a first-ever ischemic stroke between January 2000 and December 
2011, 1053 (65.7%) were excluded from the analysis because their stroke was not considered AF-related. 
Among the 549 patients with AF-related stroke, 37 (6.7%) were excluded because of in-hospital death and 
108 (19.7%) patients were excluded because of history of coronary artery disease. Among the 404 
patients (mean age 67.2±12.3, 68.2% males) who were finally included in the analysis, a statin was 
prescribed at discharge in 102 (25.2%) [supplemental figure]. The baseline characteristics of patients are 
summarized in the supplemental table. 348 (86.1%) patients had a history of AF, whereas in 56 (13.9%) 
patients AF was newly diagnosed. There were 92 cardiovascular events in 72 patients during a median 
follow-up of 22 (interquartile range: 9-48) months (table 1); there was significant difference between the 
two groups in the rate of sudden cardiac death (2% in the on-statin group vs. 10.6% in the off-statin 
group). 
 
In the multivariate Cox proportional hazards model, statin treatment was independently associated with 
lower mortality (HR: 0.49, 95%CI: 0.26-0.92, table 2) during the median 22 months follow-up.  The 
cumulative probability of survival during the median 22 months was significantly different between the 
two groups: 74.0% (95%CI: 62.1-85.9%) for the on-statin group and 59.8% (95%CI: 52.2-67.4%) for the off-
statin group (log-rank test 6.895, p<0.001, figure 1).  
 
In the multivariate Cox proportional hazards model, statin treatment was independently associated with a 
lower risk for the composite cardiovascular endpoint during the median 22 months follow-up (HR: 0.44, 
95%CI: 0.22-0.88, table 2).  The cumulative probability was significantly different between the on-statin 
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(17.4%, 95%CI: 6.2-28.6%) and off-statin groups (38.5%, 95%CI: 29.1-47.9%) (log-rank test 7.102, p=0.008, 
figure 2).  
 
In the multivariate Cox proportional hazards model, statin treatment was not associated with stroke 
recurrence during the median 22 months follow-up, despite a strong trend in favor of the on-statin group 
(HR: 0.47, 95%CI: 0.22-1.01, p=0.053, table 2).  There was a difference of borderline statistical significance 
in the cumulative probability of stroke recurrence between the on-statin (14.1%, 95%CI: 3.9-24.3%) and 
the off-statin group (29.1%, 95%CI: 20.1-38.1%) (log-rank test 3.941, p=0.047, figure 3).  
  
 
Discussion 
 
In this analysis from a large registry of consecutive patients with AF-related stroke we show that statin 
treatment is associated with improved survival and reduced risk for future cardiovascular events.  
 
Current ACC/AHA guidelines recommend high-intensity statin therapy in women and men ≤75 years of 
age with stroke of presumably atherosclerotic origin[1]. Although there is no specific recommendation 
about patients with AF-related stroke, many clinicians start statin in these patients. Our finding that statin 
is beneficial in this high-risk group is perhaps not surprising taken into consideration that statins were 
shown to be beneficial also in other high-risk non-CAD groups[1]. Given the high incidence of AF-related 
stroke and its poor prognosis[15], this finding in an observational cohort needs to be confirmed in a 
randomized trial setting. Similar findings were recently reported in an analysis of a Korean stroke 
registry[6]. 
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There was no significant difference between the on-statin and off-statin groups with regards to the 
endpoint of stroke recurrence, indicating that the beneficial effect of statins in patients with AF-related 
stroke was mainly driven by the reduction of cardiovascular rather than cerebrovascular events.  
 
Pathophysiologically, our observation may be explained by various mechanisms: first, several 
proinflammatory biomarkers are associated with increased risk for both atrial fibrillation and myocardial 
infarction, and AF has been shown to generate a proinflammatory prothrombotic milieu which may in 
turn increase the risk for myocardial infarction by promoting platelet activation, thrombin generation, 
and endothelial dysfunction[16-25]. The anti-inflammatory effects of statins may therefore prevent 
further vascular events in such patients. Second, patients with AF may suffer paroxysms of poorly 
controlled ventricular response, which may increase the oxygen demands of the myocardium and lead to 
a type 2 myocardial infarction[26]. Third, statins exert multiple pleiotropic effects which may contribute 
to their protective cardiovascular role such as immunomodulation, anti-inflammatory and antioxidant 
properties, stabilization of the atherosclerotic plaques, improved endothelial function and increased nitric 
oxide bioavailability both in patients with and without previous vascular events[27]. Also, statins are 
included among those non-arrhythmic drugs which may have a positive effect in patients with AF or in 
preventing AF in patients at risk[28, 29]. Moreover, recent evidence shows that premorbid use of statins 
in AF-related stroke patients is  associated with excellent collateral flow[30]. Lastly, the cause of stroke in 
some of our patients could have been atherosclerotic despite the presence of AF, and statin treatment 
could therefore have been particularly effective in such patients as they usually have atherosclerotic 
disease in other target organs.   
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Statin treatment was not significantly associated with stroke recurrence despite the presence of a strong 
trend (p=0.053). The major pathophysiologic type of stroke recurrence in patients with an AF-related 
index stroke is cardioembolism, often due to inadequate anticoagulation[31]. Statins do not exert an 
anticoagulant effect and hence, there is no pathophysiologic basis to support an association between 
statins and reduction in AF-related stroke recurrence. On the other hand, statins may reduce the risk of 
large-artery atherosclerotic and lacunar stroke recurrences in patients with an AF-related index stroke, 
and may also improve the above mentioned proinflammatory prothrombotic milieu.   
 
The main strengths of the present study include the assessment of hard clinical outcome measures such 
as mortality, stroke recurrence and cardiovascular events and the median follow-up period of 22 months 
in a consecutive series of stroke patients. Also, our analysis was not restricted only to dyslipidemic 
patients but included all patients irrespective of their baseline LDL levels, given that patients with AF-
related stroke is a high-risk group not only for stroke recurrence but also for future cardiovascular events 
and cardiovascular and overall mortality[3-5].  
 
Limitations 
This study is characterized by the inherent limitations of any retrospective analysis of prospectively 
collected data such as collection and entry bias, and residual confounding. Moreover, other potential 
confounders were not assessed such as adherence to statin treatment and other secondary prevention 
regimens.  Also, the efficiency of anticoagulation, i.e. the time within therapeutic range (TTR), for patients 
receiving vitamin-K antagonists was not available.  
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In conclusion, statin treatment in patients with AF-related stroke was associated with improved survival 
and reduced risk for future cardiovascular events in this long-term registry.  Given the high incidence of 
AF-related stroke and its poor prognosis, further confirmation is urgently warranted in a randomized trial 
setting in order to substantiate a novel indication for the use of statins in clinical practice. 
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Figure legends 
 
Figure 1: Kaplan-Meier curves of the 5-years’ cumulative probability of overall survival.  
 
Figure 2: Kaplan-Meier curves of the 5-years’ cumulative probability of stroke recurrence.  
 
Figure 3: Kaplan-Meier curves of the 5-years’ cumulative probability of new cardiovascular event.  
 
Supplemental figure: Flow diagram 
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Table 1: Outcome events  
 Statin treatment 
 Yes 
n=102 
No 
n=302 
p 
Stroke recurrence 8 (7.6%) 43 (14.2%) 0.214 
Myocardial infarction 1 (1%) 5 (1.7%) 1.000 
Aneurysm rupture 0 (0%) 1 (0.3%) 1.000 
Sudden cardiac death 2 (2%) 32 (10.6%) 0.006 
Total 11 (10.8%) 81 (26.8%) <0.001 
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Table 2: Multivariate Cox proportional hazard analyses showing the independent predictors of 5-years a) 
mortality, b) stroke recurrence and c) composite cardiovascular event. Numbers represent hazards ratio 
and 95% confidence intervals. 
 5-year 
mortality† 
5-year 
stroke recurrence†† 
5-year composite 
cardiovascular event††† 
Statin at discharge 0.49 (0.26-0.92) - 0.44 (0.22-0.88) 
NIHSS score (per 1 point) 1.07 (1.04-1.10) - - 
Age (per 10 years) 1.80 (1.40-2.30) 1.39 (1.05-1.85) 1.39 (1.09-1.79) 
ACE or ACE inhibitors at discharge 0.53 (0.31-0.90) 0.52 (0.27-0.99) - 
Vitamin K antagonist 0.53 (0.34-0.81) 0.42 (0.24-0.74) 0.52 (0.32-0.84) 
Diuretics - - 0.37 (0.16-0.85) 
 
† Adjusted for smoking, cholesterol on admission, antiplatelet at discharge, diuretics at discharge and brain 
edema with mass effect 
†† Adjusted for NIHSS score, smoking, ACE or ARB inhibitor at discharge, and antiplatelet at discharge.  
††† Adjusted NIHSS score, smoking, ACE or ARB inhibitor at discharge, and antiplatelet at discharge. 
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Highlights 
- We investigated whether statin treatment in patients with AF-related stroke is associated with 
improved survival and reduced risk for stroke recurrence and future cardiovascular events. 
- Among 1602 stroke patients, statin treatment was independently associated with a lower mortality 
(hazard-ratio (HR): 0.49, 95%CI: 0.26-0.92) and lower risk for the composite cardiovascular endpoint 
during the median 22 months follow-up (HR: 0.44, 95%CI:0.22-0.88), but not with stroke recurrence 
(HR: 0.47, 95%CI:0.22-1.01, p:0.053). 
- Statin treatment was associated with improved survival and reduced risk for future cardiovascular 
events 
